



Aktuelle Studien

der Medizinischen Klinik 3
Rotkreuzklinikum München

Indikation	Kurztitel	Vollständiger Titel
		AMG-Studien
Testicular cancer	Acousia 02 EudraCT number 2023-503696-15-00	Phase IIa randomized, double-blind, and placebo-controlled multicenter split body trial to determine safety, tolerability, and efficacy of repeated doses of ACOU085 for the prevention of hearing loss in testicular cancer patients receiving cisplatin
AML	TUD-MOSAIC-078	MidOStaurin + Gemtuzumab OzogAmlcin Combination in Firstline Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
T-Cell Lymphoma	_KILT EudraCT number 2020 003735 16	A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA
AML	Vincent	Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 mutations eligible for intensive treatment (VINCENT)

Sonstige Studien

AML	AML- Register	AML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL) und der AML Cooperative Group (AML-CG)
ALL	GMALL-Register	GMALL-Register und Biomaterialbank Biomaterialsammlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen
MCL	EMCL-Registry	The Registry of the European Mantle Cell Lymphoma study group – MCL: Disease pattern, treatment algorithms and mechanisms of relapse
	HIV-Lymphoma Register	Characteristics, treatment and outcomes of HIV-infected patients with malignant lymphoma: A registry study of the EHA lymphoma group
Lymphom	T-NHL-Register	T-ZELL LYMPHOM REGISTER UND BIOMATERIALBANK DER GERMAN LYMPHOMA ALLIANCE (GLA) DER OSTDEUTSCHEN STUDIENGRUPPE FÜR HÄMATOLOGIE UND ONKOLOGIE (OSHO)
MM	MMML Predict	Molecular Mechanisms in Malignant Lymphoma - MMML-Predict